The Carle Heart and Vascular Institute is one of the largest cardiovascular institutes in Illinois. Our cardiologists, cardiac surgeons, vascular surgeons and interventional radiologists treat more than 30,000 patients in Illinois, Indiana and the region each year. They offer unparalleled experience in caring for patients with heart and blood vessel diseases.
What does that mean to you as a patient? It means you’ll have access to the area’s largest and most specialized care providers in the state. It means you don’t have to travel to far destinations to receive excellent care.
Caregivers from the Heart and Vascular Institute's four departments - Cardiovascular Medicine, Cardiac Surgery, Vascular Surgery and Interventional Radiology - collaborate with other medical and surgical specialties to provide the highest level of patient care, research and education to patients with cardiac, vascular and related conditions.
Have a patient referral? Refer a patient now.
Research is a core mission of Carle Heart and Vascular Institute (HVI). HVI works closely with the Stephen’s Family Clinical Research Institute to offer patients leading-edge therapies through clinical trials. Our physician investigators (cardiologists, cardiac surgeons, vascular surgeons and radiologists) are involved in multiple national and investigator-initiated studies that span the field of pharmacotherapy and interventional devices. Also, HVI is actively involved in translational research activities in collaboration with the Beckman Institute for Advanced Science and Technology.
The Cryo AF Global Registry is a prospective, global, multi-center, observational post-market registry (PMR). The purpose of this study is to evaluate and describe clinical performance and safety data in a broad patient population treated with a commercially available Arctic Front™ Family of Cardiac Cryoablation Catheters (hereafter referred to as "Arctic Front™ Cardiac Cryoablation Catheter System"). The cryoballoon ablation(CBA) procedure will be performed according to routine hospital practice. The study is expected to have a 24 month enrollment period. The follow up period is intended to align with standard practice and subjects will be followed for a minimum of 12 months post-procedure.
The purpose of this registry (“the PERT Registry”) is to gather data on patients diagnosed with pulmonary embolism, treated by the Pulmonary Embolism Response Team (PERT) at each site and beyond for epidemiologic, therapeutic, quality assessment and outcomes research.
While there are several completed clinical trials that address treatment strategy in patients with symptomatic and recurrent AF, there are no randomized clinical trials that address treatment for first-detected AF. In usual care, these patients are started on an atrioventricular nodal blocking agent (beta-blocker or non-dihydropyridine calcium channel blocker) along with stroke prevention therapy. The investigators hypothesize that earlier administration of a well-tolerated antiarrhythmic drug proven to reduce hospitalization may result in improved cardiovascular outcomes and quality of life in patients first-detected AF. The purpose of this study is to determine if treatment with dronedarone on top of usual care is superior to usual care alone for the prevention of cardiovascular hospitalization or death from any cause in patients hospitalized with first-detected AF. All patients will be treated with guideline-recommended stroke prevention therapy according to the CHA2DS2-VASc score. The treatment follow-up period will be 12 months. There will be two follow-up visits. Consistent with the pragmatic nature of the trial, the first follow-up will occur between 3 -9 months and the 2nd will occur at 12 months (with a window of +/- 30 days). Approximately 3000 patients will be enrolled and randomly assigned (1:1) to study intervention. The study intervention will be dronedarone 400 mg twice daily in addition to usual care versus usual care alone.
With doctors practicing in 80 specialties at locations throughout the region, it’s easy to find the right healthcare team at Carle. Our mission is to serve people through high quality care, medical research and education.
“With Jac and other afib patients, we aim to minimize or prevent recurrence for as long as possible and restore quality of life.”DONATE NOW READ FULL ARTICLE
Recognized among the nation’s top hospitals, Carle provides excellent healthcare while continuously improving to meet the needs of our patients.